Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Aigen Investment Management LP

Aigen Investment Management LP lessened its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 29.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,376 shares of the company’s stock after selling 2,661 shares during the period. Aigen Investment Management LP’s holdings in Twist Bioscience were worth $296,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TWST. Massachusetts Financial Services Co. MA boosted its holdings in shares of Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after buying an additional 20,035 shares in the last quarter. Barclays PLC boosted its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after buying an additional 104,420 shares in the last quarter. FMR LLC boosted its holdings in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after buying an additional 12,327 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $1,059,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares in the last quarter.

Twist Bioscience Stock Up 0.6 %

TWST stock opened at $39.43 on Friday. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -11.67 and a beta of 2.15. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a fifty day moving average price of $46.54 and a 200 day moving average price of $45.46.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.75) EPS. Sell-side analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

TWST has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Finally, TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

Insiders Place Their Bets

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the transaction, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This represents a 13.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,654 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $74,264.60. Following the completion of the transaction, the chief executive officer now owns 673,064 shares of the company’s stock, valued at $30,220,573.60. This represents a 0.25 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,007 shares of company stock worth $1,446,933. 3.01% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.